Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
7
Number of overlapping holdings
23.3%
% of MEDX's 30 holdings also in CANC
14.6%
% of CANC's 48 holdings also in MEDX
Overlap by Weight
Sector Drift (MEDX minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in MEDX |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
ELI LILLY & CO | 16.8% | 5.3% | 5.3% |
|
BRISTOL-MYERS SQUIBB CO | 6.5% | 4.5% | 4.5% |
|
AMGEN INC | 6.3% | 2.9% | 2.9% |
|
MERCK & CO. INC. | 3.6% | 2.9% | 2.9% |
|
ABBVIE INC | 9.6% | 2.1% | 2.1% |
Position Highlights (Non-Overlapping Exposures)
MEDX Overweight Relative to CANC
|
ELI LILLY & CO | 11.5% |
|
ABBVIE INC | 7.5% |
 |
NOVARTIS AG-ADR | 6.6% |
 |
ASTRAZENECA PLC-SPONS ADR | 5.6% |
|
JOHNSON & JOHNSON | 5.1% |
|
ALNYLAM PHARMACEUTICALS INC | 4.7% |
 |
ALKERMES PLC | 4.7% |
|
PFIZER INC | 4.0% |
|
AMGEN INC | 3.4% |
|
GLAXOSMITHKLINE PLC-SPON ADR | 2.7% |
MEDX Underweight Relative to CANC
|
REVOLUTION MEDICINES, INC. | -5.4% |
|
ROCHE HOLDINGS LTD-SPONS ADR | -5.2% |
|
ASTRAZENECA PLC | -4.3% |
|
NOVARTIS AG | -4.2% |
|
BRIDGEBIO PHARMA, INC. | -4.1% |
|
EXELIXIS INC | -4.0% |
|
NUVALENT, INC. CLASS A | -3.8% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.7% |
 |
GENMAB A/S SPONSORED ADR | -3.1% |
 |
MERUS N.V. | -3.1% |